Five Prime Therapeutics Inc. (FPRX) and Histogenics Corporation (NASDAQ:HSGX) Contrasting side by side

Five Prime Therapeutics Inc. (NASDAQ:FPRX) and Histogenics Corporation (NASDAQ:HSGX) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Five Prime Therapeutics Inc. 59.05M 6.86 130.91M -4.03 0.00
Histogenics Corporation N/A 0.00 13.78M -0.43 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Five Prime Therapeutics Inc. and Histogenics Corporation.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Five Prime Therapeutics Inc. -221.69% -41.5% -33.9%
Histogenics Corporation 0.00% 66.4% -73.3%

Risk and Volatility

Five Prime Therapeutics Inc. has a 3.12 beta, while its volatility is 212.00%, thus making it more volatile than Standard & Poor’s 500. Histogenics Corporation’s 11.00% less volatile than Standard & Poor’s 500 volatility due to the company’s 0.89 beta.


The Current Ratio and a Quick Ratio of Five Prime Therapeutics Inc. are 8.4 and 8.4. Competitively, Histogenics Corporation has 0.7 and 0.7 for Current and Quick Ratio. Five Prime Therapeutics Inc.’s better ability to pay short and long-term obligations than Histogenics Corporation.

Analyst Recommendations

The table shown features the ratings and recommendations for Five Prime Therapeutics Inc. and Histogenics Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Five Prime Therapeutics Inc. 0 0 3 3.00
Histogenics Corporation 0 2 0 2.00

$34 is Five Prime Therapeutics Inc.’s average target price while its potential upside is 197.72%. On the other hand, Histogenics Corporation’s potential upside is 2,594.38% and its average target price is $3.5. The data provided earlier shows that Histogenics Corporation appears more favorable than Five Prime Therapeutics Inc., based on analyst belief.

Insider & Institutional Ownership

Roughly 88.3% of Five Prime Therapeutics Inc. shares are owned by institutional investors while 17.8% of Histogenics Corporation are owned by institutional investors. 2.4% are Five Prime Therapeutics Inc.’s share owned by insiders. Comparatively, 6.2% are Histogenics Corporation’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Five Prime Therapeutics Inc. -5.84% 8.63% -7.43% -29.71% -47.75% -44.84%
Histogenics Corporation 8.67% -13.07% -25.83% -83.15% -75.9% -77.31%

For the past year Five Prime Therapeutics Inc.’s stock price has smaller decline than Histogenics Corporation.


On 6 of the 11 factors Five Prime Therapeutics Inc. beats Histogenics Corporation.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.